in 2024, NemaGen received multiple grants from the New Jersey Economic Development Authority, CSIT, including a phase I SBIR bridge grant, a phase II SBIR bridge grant, and a catalyst voucher award that allowed us to conduct studies with NJ-based core facilities. We are thrilled to have received these awards, and are very grateful to NJEDA-CSIT for their support!
To further support our drug development, NemaGen participated in an NIH I-Corps Program March-April 2023 to speak with various stakeholders to better understand their needs and validate our therapy's value. This program also comes with a $55,000 grant award. Thanks to NCATS for further supporting our efforts to develop therapies treating mastocytosis and other mast cell-related diseases!
NemaGen is honored and excited to announce that we were awarded an NIH Small Business Innovation Research grant. We would like to thank the NIH and NCATS for recognizing the significance and impact of our work focused on treating mastocytosis and other mast cell-related diseases.